Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation - Impact of specific HER1 inhibition

Prostate

Volumn 64, Issue 1, 2005, Pages 1-8

  Tørring, Niels ^a   Hansen, Frederik Dagnæs ^b   Sørensen, Boe Sandahl ^a   Ørntoft, Torben F ^a   Nexø, Ebba ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Castration; EGF; EGF receptor; Tyrosine kinase

Indexed keywords

AMPHIREGULIN; ANDROGEN; EPIDERMAL GROWTH FACTOR; EPIREGULIN; GEFITINIB; PLACEBO; PROTEIN HER1; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CASTRATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANDROGENS; ANIMALS; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION; GLYCOPROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 19544376821     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20214     Document Type: Article

References (29)

1. Navarro D, Luzardo OP, Fernandez L, Chesa N, Diaz-Chico BN. Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 2002;81:191-201.
2. de la Taille A, Vacherot F, Salomon L, Druel C, de Medina SGD, Abbou C, Buttyan R, Chopin D. Hormone-refractory prostate cancer: A multi-step and multi-event process. Prostate Cancer Prostatic Dis 2001;4:204-212.
3. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110.
4. Schuurmans ALG, Bolt J, Veldscholte J, Mulder E. Regulation of growth of LNCaP human prostate tumor-cells by growth-factors and steroid-hormones. J Steroid Biochem Mol Biol 1991;40:193-197.
5. Lin JQ, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999;59:2891-2897.
6. Tørring N, Jørgensen PE, Sørensen BS, Nexø E. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha, and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000;20:91-95.
7. Ciardiello F, Caputo R, Bianco R, Pomatico G, Damiano V, De Placido S, Bianco AR, Tortora G. Antitumor effects and potentiation of cytotoxic drugs activity in human cancer cell lines by ZD-1839 (Iressa™), an EGFR-specific tyrosine kinase inhibitor. Clin Cancer Res 1999;5:3735S.
8. Sørensen BS, Tørring N, Bor MV, Nexø E. Quantitation of the mRNA expression of the epidermal growth factor system: Selective induction of heparin-binding epidermal growth factor-like growth factor and amphiregulin expression by growth factor stimulation of prostate stromal cells. J Lab Clin Med 2000;136:209-217.
9. Tørring N, Møller-Ernst JK, Lund L, Nielsen JE, Djurhuus JC, Poulsen SS, Nexø E. Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: A placebo-controlled randomized study. BJU Int 2002;89:583-590.
10. Christensen ME, Engbaek F, Therkildsen MH, Bretlau P, Nexø E. A sensitive enzyme-linked-immunosorbent-assay used for quantitation of epidermal growth-factor receptor protein in head and neck carcinomas-Evaluation, interpretations, and limitations. Br J Cancer 1995;72:1487-1493.
11. Jørgensen PE, Eskildsen L, Nexø E. Adsorption of EGF receptor ligands to test tubes - A factor with implications for studies on the potency of these peptides. Scand J Clin Lab Invest 1999;59: 191-197.
12. Myers RB, Oelschlager D, Manne U, Coan PN, Weiss H, Grizzle WE. Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma. Int J Cancer 1999;82:424-429.
13. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function, and possible role in clinical trials. Ann Oncol 1997;8: 1197-1206.
14. Seth D, Shaw K, Jazayeri J, Leedman PJ. Complex post transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells. Br J Cancer 1999;80:657-669.
15. Thøgersen VB, Sørensen BS, Poulsen SS, Ørntoft TF, Wolf H, Nexø E. A subclass of HER1 ligands is a prognostic marker for survival in bladder cancer patients. Cancer Res 2001;61:6227-6233.
16. Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Buchler MW. Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen 2001;21:27-44.
17. D'Antonio A, Losito S, Pignata S, Grassi M, Perrone F, De Luca A, Tambaro R, Bianco C, Gullick WJ, Johnson GR, Iaffaioli VR, Salomon DS, Normanno N. Transforming growth factor alpha, amphiregulin, and cripto-1 are frequently expressed in advanced human ovarian carcinomas. Int J Oncol 2002;21:941-948.
18. Tørring N, Dagnaes-Hansen F, Sørensen BS, Nexø E, Hynes NE. ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate 2003;56:142-149.
19. Sørensen BS, Tørring N, Bor MV, Nexø E. The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol Cell Biochem 2004;260:129-135.
20. Miyazaki Y, Hiraoka S, Tsutsui S, Kitamura S, Shinomura Y, Matsuzawa Y. Epidermal growth factor receptor mediates stress-induced expression of its ligands in rat gastric epithelial cells. Gastroenterology 2001;120:108-116.
21. Lindvall C, Hou M, Komurasaki T, Zheng CY, Henriksson M, Sedivy JM, Bjorkholm M, Teh BT, Nordenskjold M, Xu DW. Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: Activation of the epiregulin gene. Cancer Res 2003;63:1743-1747.
22. Vlietstra RJ, van Alewijk DCJG, Hermans KGL, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998;58:2720-2723.
23. Simpson L, Parsons R. PTEN: Life as a tumor suppressor. Exp Cell Res 2001;264:29-41.
24. Carson JP, Kulik G, Weber MJ. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B. Cancer Res 1999;59:1449-1453.
25. Mellinghoff IK, Tran C, Sawyers CL. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 2002;62:5254-5259.
26. Sirotnak FM, She Y, Lee F, Scher HI. Studies with CWR22 xenograft models in nude mice suggest that ZD1839 (Iressa) may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 2001;7:3762S-3763S.
27. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-4302.
28. Shelly M, Pinkas-Kramarski R, Guarino BC, Waterman H, Wang LM, Lyass L, Alimandi M, Kuo A, Bacus SS, Pierce JH, Andrews GC, Yarden Y. Epiregulin is a potent Pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem 1998;273:10496-10505.
29. Hurbin A, Dubrez L, Coll JL, Favrot MC. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J Biol Chem 2002;277:49127-49133.